Sagimet Biosciences Inc.
SGMT
$2.21
$0.199.41%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | 0.00 | 2.00M | 2.00M | 2.00M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | 0.00 | 2.00M | 2.00M | 2.00M |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | 0.00 | 2.00M | 2.00M | 2.00M |
| SG&A Expenses | 16.01M | 15.84M | 16.09M | 14.19M | 12.96M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 54.45M | 45.73M | 38.28M | 34.74M | 32.74M |
| Operating Income | -54.45M | -45.73M | -36.28M | -32.74M | -30.74M |
| Income Before Tax | -45.57M | -37.52M | -29.25M | -27.92M | -27.88M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -45.57 | -37.52 | -29.25 | -27.92 | -27.88 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -45.57M | -37.52M | -29.25M | -27.92M | -27.88M |
| EBIT | -54.45M | -45.73M | -36.28M | -32.74M | -30.74M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -1.44 | -1.29 | -1.18 | -36.73 | -72.08 |
| Normalized Basic EPS | -0.90 | -0.80 | -0.74 | -22.95 | -45.05 |
| EPS Diluted | -1.44 | -1.29 | -1.18 | -36.73 | -72.08 |
| Normalized Diluted EPS | -0.90 | -0.80 | -0.74 | -22.95 | -45.05 |
| Average Basic Shares Outstanding | 125.29M | 116.54M | 102.59M | 70.87M | 42.02M |
| Average Diluted Shares Outstanding | 125.29M | 116.54M | 102.59M | 70.87M | 42.02M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |